Report: More than half of the world's population will be overweight/obese by 2035

Published Date: 08 Mar 2023

The World Health Organization's 2023 Atlas predicts that 51% of the world's population, or more than 4 billion people, will be overweight or obese within the next 12 years.

Read Full News

Latest News

Use Of GLP-1 Drugs Early in Pregnancy Should Not Cause Alarm, Analysis Suggests

Use of GLP-1 drugs for diabetes or obesity early in the first trimester of pregnancy, before a woman realizes she is pregnant, is ⁠not a cause for alarm, a large new data...

Study Finds No Link Between Semaglutide and AMD Risk

Compared with other glucose-lowering drugs, semaglutide is not associated with the risk for neovascular age-related macular degeneration in adults with type 2 diabetes.

Can GLP-1s Curb Cancer Progression?

A real-world analysis links GLP-1s to substantially lower rates of metastatic progression in four cancers associated with obesity and/or diabetes — but experts urged caution to interpret the findings.

Skin Disorders in Transgender Patients: Treatment Tips

Dermatologists highlight the risks for acne, hair loss and unwanted hair, and melasma, as well as recent data on hidradenitis suppurativa.

Weekly and Monthly Berobenatide Show Weight, A1c Benefits

The long-acting GLP-1 drug had good overall tolerability with some GI bumps in weekly-to-monthly transition, while the A1c benefits raise hopes of a potential ‘game changer’ for T2D.

Roche Obesity Drug Helps Patients Shed 22.7% Of Weight in Mid-stage Trial

Roche said on Friday that patients lost 22.7% of their body weight in a mid-stage trial of its dual-acting experimental obesity ⁠drug, with more than a quarter of those who...

Todays Updates

Simpler Screening Criteria Could Catch More Lung Cancers

A study of nearly 1 million veterans suggests that simpler lung cancer screening eligibility — based on smoking duration — would sharply reduce missed cancers and narrow disparities.

Breast Cancer Genetic Testing Need in Black Women Identified

A large population study of young Black women aged 50 years or younger with invasive breast cancer highlights the importance of genetic testing in this population.

NHS Offers Targeted Radiotherapy for Early Prostate Cancer

Eligible men with early prostate cancer can now be offered a high-precision radiotherapy technique on the NHS in England.

Todays Updates

Simpler Screening Criteria Could Catch More Lung Cancers

A study of nearly 1 million veterans suggests that simpler lung cancer screening eligibility — based on smoking duration — would sharply reduce missed cancers and narrow disparities.

Breast Cancer Genetic Testing Need in Black Women Identified

A large population study of young Black women aged 50 years or younger with invasive breast cancer highlights the importance of genetic testing in this population.

NHS Offers Targeted Radiotherapy for Early Prostate Cancer

Eligible men with early prostate cancer can now be offered a high-precision radiotherapy technique on the NHS in England.

Latest News

Use of GLP-1 drugs for diabetes or obesity early in the first trimester of pregnancy, before a woman realizes she is pregnant, is ⁠not a cause for alarm, a large new data...

Compared with other glucose-lowering drugs, semaglutide is not associated with the risk for neovascular age-related macular degeneration in adults with type 2 diabetes.

A real-world analysis links GLP-1s to substantially lower rates of metastatic progression in four cancers associated with obesity and/or diabetes — but experts urged caution to interpret the findings.

Dermatologists highlight the risks for acne, hair loss and unwanted hair, and melasma, as well as recent data on hidradenitis suppurativa.

The long-acting GLP-1 drug had good overall tolerability with some GI bumps in weekly-to-monthly transition, while the A1c benefits raise hopes of a potential ‘game changer’ for T2D.

Roche said on Friday that patients lost 22.7% of their body weight in a mid-stage trial of its dual-acting experimental obesity ⁠drug, with more than a quarter of those who...

News All Time

CGM Monitoring Benefits Extend to Non-Insulin-Using T2D

Patients with type 2 diabetes not taking insulin who use continuous glucose monitoring show significant reductions in A1c.

Obesity Meds Improve Patients' Perceived Physical Function

Obesity management medications improve patients' perceived physical function and have a 'modest' impact on an objective functional measure.

GLP-1 QOL Benefits Greatest for Those With Obesity Plus T2D

Patients with obesity and type 2 diabetes have more favorable QOL outcomes taking a GLP-1 than those with either condition alone or with multiple comorbidities.

Danish Study Links Type 1 Diabetes to Femoral Fractures

Both T1D and T2D are linked to a higher incidence of subtrochanteric or femoral shaft and hip fractures, but after adjusting for age, only the association for T1D remains significant.

Glucose Excursions Drive CGM-A1c Discordance in Monitoring

Discordance between continuous glucose monitoring measures and A1c should not always be interpreted as measurement errors, according to a new study.

Primary Infertility Linked to Earlier Menopause Onset

Women with primary infertility undergo natural menopause earlier than women without infertility.

Exclusive-Cigna Drops Coverage Of GLP-1 Obesity Drugs for Its Own Employees

Health insurer Cigna will stop covering GLP-1 weight-loss drugs including Novo Nordisk's Wegovy and Eli Lilly's Zepbound in its employee ⁠health plan effective July 1,...

How Cannabis Compounds May Help Create Weight-Loss Drugs

A new study in mice finds that cannabis extracts improve glucose regulation by improving communication between fat cells and the pancreas.

Phase 3: Rapid Relief in Thyroid Eye Disease With Veligrotug

A five-infusion course of veligrotug is well tolerated and results in rapid improvements in diplopia, proptosis, and disease activity in patients with thyroid eye disease, a phase 3 trial shows.

SGLT2 Inhibitors Cut Kidney Events in Nephrotic Proteinuria

In adults with type 2 diabetes and nephrotic-range proteinuria, SGLT2 inhibitors are linked to lower risks for major adverse kidney events and all-cause mortality than DPP-4 inhibitors.

BMI at Age 6 Predicts Obesity Risk in Young Adulthood

BMI at age 6 strongly predicts the risk for overweight and obesity in young adulthood; children with a high BMI and slower growth between ages 2 and 6 have odds similar to peers with an average BMI.

Gestational Diabetes May Raise Future Retinopathy Risk

In women with diabetes, a history of gestational diabetes is associated with a higher risk for diabetic retinopathy, with risk increasing as gestational diabetes severity increases.

Gestational GLP-1s Tied to Adverse Obstetric Outcomes

Underlying diabetes and discontinuation rebound in mothers with overweight are likely responsible rather than the drug itself.

Eating Out Exacerbating the Global Obesity Epidemic

Eating out instead of preparing food at home is exacerbating the global obesity epidemic, with half of adults worldwide eating out at least once a week.

GLP-1 Apps: Helpful Companions or False Sense of Security?

GLP-1 consumer apps can help patients stay on track but have no evidence base; clinical-grade apps can do more but are not accessible to most patients.

Fezolinetant Linked to Enzyme Elevations

Fezolinetant is associated with a hepatic adverse event reporting signal characterized primarily by transaminase elevations rather than clinically overt liver injury.

Recommended News For You

Gene Therapy for Rare Brain Disease Effective, but Comes With Blood Cancer Risk

Clinical trial could lead to new 'gold standard' test for prostate cancer detection

Proton Therapy Fails to Beat IMRT in Prostate Cancer

EGFR Inhibitors for Lung Cancer Tied to Increased Keratitis Risk.

A small rise in cancer was observed following the 1986 Chernobyl accident.

In Advanced Myxoid Liposarcoma, Is Trabectedin Winning?

Pancreatic cancer RNA vaccine shows durable T cell immunity

Recommended Articles For You

Lactic Acid-Linked lncRNAs in Wilms Tumor: Decoding the Tumor Microenvironment & Prognosis 

Discovering the Benefits of TNK: A Comprehensive Blog Article  

Understanding Blood Dyscrasia: Symptoms, Causes and Treatment Options 

Understanding the Rare Disease: Werner Syndrome Explained  

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Using AI, one can find cancer risk factors.

2.

New Gene Therapy Nears EU Nod for Bladder Cancer

3.

How breast tissue density affects your risk of breast cancer

4.

Young adults who are obese are at risk for 17 different types of cancer in the future.

5.

Distinct results for patients with positive and negative pancreatic cancer who are treated with systemic therapy, chemotherapy, and radiation.

1.

Mechanistic Insights into Abraxane, Verzenio, and the Management of Chemotherapy-Induced Tachycardia

2.

CAR-T Cell Therapy for Diffuse Large B-Cell Lymphoma: A Comprehensive Review

3.

Analyzing the Mechanisms and Efficacy of Carboplatin, Abraxane, and Albumin-Bound Formulations

4.

Revolutionizing Oncology Trials: Optimization, Matching, Diversity, and Decentralization

5.

Evolution of Cancer Care Through Developmental Therapeutics

1.

Asian Symposium on Advancement in Hematology and Oncology

2.

International Cancer Conference

3.

Asian Symposium on Advancement in Hematology and Oncology

4.

Asian Symposium on Advancement in Hematology and Oncology

5.

International Lung Cancer Congress®

1.

Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part I

2.

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part V

3.

The Evolving Landscape of First-Line Treatment for Urothelial Carcinoma

4.

Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VII

5.

Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part I

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot